SWM
BBC icon

Spire Wealth Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Spire Wealth Management’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$8K – 2534
2021
Q4 		$8K Buy
+200
New +$8.53K ﹤0.01% 2435

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Spire Wealth Management's BBC Position: Q1 2022 in Review

Spire Wealth Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2022, closing a stake of 200 shares — an estimated $8K sold.

Spire Wealth Management first reported a position in BBC in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 18 funds tracked by Wall St. Rank hold BBC as of Q1 2022.

  • Spire Wealth Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 200 Virtus Biotech Clinical Trials ETF shares in Q1 2022, an estimated $8K.
  • Spire Wealth Management first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2021 and held it in 1 quarter.
  • Spire Wealth Management's Virtus Biotech Clinical Trials ETF position peaked at $8K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.